The foundation of this observation lies in the EOMES transcriptional signature that we first defined and associated with TIGIT+ KLRG1+ CD8 T cells in T1D responders to teplizumab (anti-CD3) therapy (12) and here extended to HC, cancer, and chronic viral infection. This evidence concerns the gene CD8A and type 1 diabetes mellitus.